BioNTech appoints Kylie Jimenez as its first Chief People Officer, a strategic move aimed at building the organizational and cultural backbone for its ambitious transition into a multi-product oncology company by 2030.
Gilead Sciences, the biopharma giant known for its HIV treatments, is strategically pivoting to become a major player in cancer therapy. Through targeted licensing and a focus on precision oncology, the company aims to build a multi-billion dollar revenue stream by the end of the decade, reducing its reliance on mature franchises.
In an exclusive interview, GeneDx CEO Katherine Stueland details how rapid genomic testing is transforming pediatric care, slashing diagnosis times from years to days and building a data-driven bridge to future therapies.
Meta Platforms is hit with a patent infringement lawsuit by Solos Technology, targeting core components of its smart glasses. The legal challenge could disrupt product development and partnerships in a key growth area for the tech giant.
Elon Musk's SpaceX has finalized the acquisition of his artificial intelligence venture, xAI, in a strategic move that merges the aerospace giant with the creator of the Grok chatbot. The deal, valued at a staggering $1.25 trillion, aims to accelerate AI development by leveraging shared computing resources and engineering talent from Musk's broader technology portfolio.
MicroStrategy's massive Bitcoin holdings have fallen below their average purchase price, resulting in over $900 million in paper losses. This development intensifies scrutiny on the company's reliance on equity markets to fund its crypto acquisitions as financial conditions tighten.
In a rare show of common cause, both government supporters and opponents took to the streets of Caracas on Monday, demanding better salaries and pensions as the interim administration promises an oil-fueled recovery.
U.S. corn futures edged lower at Monday's midday, pressured by a stronger dollar, falling crude oil, and a weekly export inspections report that fell short of last year's pace. The market also digested trade developments with India and positioning data from speculators.
Google's unveiling of Project Genie, an AI tool for generating interactive 3D worlds, sends ripples through the game development sector, directly challenging incumbent platform Unity Software. The announcement coincides with a period of intense volatility and investor scrutiny for Unity, raising fundamental questions about its long-term strategic position in an AI-driven landscape.
Elon Musk is reportedly advancing plans to merge his aerospace giant SpaceX with his artificial intelligence venture xAI, a move that could funnel significant capital into AI development and reshape the tech landscape, according to a Wall Street Journal report.
U.S. stocks advanced cautiously Monday as investors braced for a wave of corporate earnings reports, while crude oil prices tumbled sharply. The focus remains on key tech results and evolving geopolitical developments affecting global trade and energy markets.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
Chinese regulators have greenlit the first wave of Nvidia's advanced H200 AI chip orders for major firms including Alibaba and ByteDance, marking a potential turning point for the chipmaker's access to a critical market and fueling optimism for its stock trajectory.
Spanish healthtech startup Biorce has closed a substantial Series A round, backed by prominent venture capital and angel investors, to scale its AI-driven clinical trial solution, Aika, internationally amid a tightening regulatory landscape.
The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.
Synthetic biology leader Twist Bioscience reported strong Q1 FY2026 results, with revenue climbing 17% year-over-year to $103.7 million. Management highlighted accelerating demand from AI-powered drug discovery and reiterated its path to adjusted EBITDA breakeven by Q4 FY2026.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Investment firm Curreen Capital, known for targeting undervalued 'ugly duckling' companies, highlighted contract research organization Fortrea Holdings as a prime example of its strategy in its latest investor letter. The firm reported a 30.97% return for 2025.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
